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by Michael addition reaction retained enzymatic
activity†
D. R. Garcia and N. Lavignac*
Polymer–protein conjugates are key to overcome some of the therapeutic protein limitations, including
ineﬃcient intracellular delivery. Poly(amidoamine)s are bioresponsive polyelectrolytes, which can form
complexes with proteins and promote their delivery into the cytosol of cells. To investigate if conjugation
would aﬀect the activity of the protein, two poly(amidoamine)–BSA conjugates were synthesised using a
“grafted to” method and Michael addition reaction. Following puriﬁcation, the conjugates were character-
ised by electrophoresis, size exclusion chromatography (Mn(C1) = 140.7 kDa; Mn(C2) = 218.6 kDa) and
light scattering (Dh(C1) = 37.5 nm; Dh(C2) = 75.1 nm). As a result of the conjugation with the cationic
polymer, the conjugates had a positive zeta potential (ζ(C1) = +15.4 mV; ζ(C2) = +20.2 mV). TNBS assays
demonstrated that 16% to 25% of the protein amine groups were modiﬁed and HPLC analysis indicated
that the amount of protein in the conjugate was 0.76 mg of BSA mg−1 of PAA (C1) and 0.43 mg of BSA
mg−1 of PAA (C2). Enzymatic assays indicated the conjugates displayed an esterase activity similar (C1) or
reduced ∼35% (C2) compared to BSA. Altogether the results demonstrated that the conjugation of poly
(amidoamine)s to a model protein can lead to the formation of bioconjugates that retain the enzymatic
activity of the native protein. Such conjugates could have some application in protein delivery and
enzyme engineering for biocatalysis and biosensors.
Introduction
Polymer–protein conjugates are hybrid materials that display
properties generally derived from biological (i.e. the protein)
and synthetic (i.e. the polymer) components. Since the
1970s1,2 interest in such bioconjugates has increased exponen-
tially due to their ability to overcome some of the protein limit-
ations. These semi-synthetic materials have been developed
for a range of applications, including nanomedicine, biocataly-
sis and biosensors,3–5 to overcome issues mostly related to
protein stability or delivery eﬃciencies. The physicochemical
characteristics of the synthetic polymers can be tailored to
obtain properties suitable to their applications. Polymers
selected for the synthesis of biopharmaceuticals should be
water-soluble, non-toxic, non-immunogenic, well defined, and
be biodegradable and/or be easily eliminated from the body.
In this context, one of the most commonly used polymers is
poly(ethylene glycol) (PEG).6 PEG has been used to prepare
numerous conjugates (e.g. Oncaspar®, Pegasys®, CIMZIA®) to
treat diﬀerent diseases with pegylated proteins exerting their
pharmacological eﬀect either in the blood circulation or on
membrane receptors. However, in recent years, pegylation has
faced a number of challenges7,8 and other polymers (e.g. poly-
sialic acid, poly(2-oxazoline)s, PNIPAM, PEGMA) have been the
subject of increasing research as potential alternative.
Polymer–protein conjugates are generally synthesised either
via a “grafting to” or “grafting from” method. The former
relies on coupling techniques between the protein and a pre-
formed polymer, whereas the latter relies on in situ controlled
radical polymerisation in which the polymer chains can grow
directly from the protein.8,9 Both methods have advantages
and disadvantages. “Grafting from” approaches usually use
metal catalysts or unstable reagents which could favour
protein denaturation and may limit future clinical applications
of the conjugates due to cytotoxicity. “Grafting to” conju-
gations can lead to low grafting densities and usually require
an excess of polymer which may imply extensive purification.
However to date, the approved polymer–protein conjugates
have all been obtained via a “grafting to” method.6,7
Poly(amidoamine)s (PAAs) are “smart”, water-soluble poly-
mers known for their ability to enter the cells by endocytosis.10,11
They are pH-responsive and at low pH, protonation of amino
groups arranged regularly along the polymer backbone
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induces conformational changes potentially facilitating inter-
actions with biological membranes. In contrast to PEG, they
are degradable and have been used as nanocarriers for the
intracellular delivery of drugs12,13 and biomacromolecules,
including proteins.14,15 Bioconjugation can lead to a decrease
of the protein biological activity.6,7,16 If PAAs were to be used
to develop polymer–protein conjugates, the resulting hybrids
should retain some activity. In the present work, bioconjugates
between a cationic poly(amidoamine) and bovine serum
albumin (BSA) were synthesised using a “grafting to” method.
The conjugation was carried out under mild conditions suit-
able for biologicals. The hydrogen-transfer reaction between
amino groups and activated vinyl groups was carried out at
diﬀerent pH in an aqueous environment. The conjugates were
purified by ionic exchange and size exclusion chromatography
and the enzymatic activities were determined and compared




BSA, NaHCO3, TRIS, methanol, coomassie blue, H2O (HPLC
grade), acetic acid, CH3COONa·3H2O, NaCl, NaN3, urea, SDS,
Na2HPO4·7H2O, NaH2PO4·H2O were from Fisher. Piperazine
hexahydrate, acetonitrile, glycerol and p-nitrophenyl acetate
were from Acros Organics. Acryloyl chloride was from Alfa
Aesar. NaOH, HCl, anhydrous MgSO4, hexane, dichloro-
methane, 2-methylpiperazine, N,N′-bis(2-hydroxyethyl)ethylene-
diamine), trinitrobenzene sulfonate (TNBS), glycine, thyro-
globulin (669 kDa), apoferritin (443 kDa), alcohol dehydro-
genase (150 kDa) and carbonic anhydrase (29 kDa) were from
Sigma. Deuterated dimethyl sulfoxide (DMSO-d6) with tetra-
methylsilane (TMS), deuterated water (D2O) and 4,4-dimethyl-
4-silapentane-1-sulfonic acid (DSS) were from CIL. The NMR
spectra were acquired on an ECA FT NMR spectrometer (Jeol)
and the chemical shifts were determined relative to internal
reference peak (i.e. TMS or DSS – 1H-NMR) or solvent peak (i.e.
13C-NMR).
Synthesis of N,N′-bis(acryloyl)piperazine (BAP) (3)
10 g (0.051 mol) of piperazine hexahydrate (1) was dissolved in
51.55 mL of dichloromethane. A solution of NaOH (4.32 g,
0.11 mol) in H2O (10.3 mL) and a solution of acryloyl chloride
(2) (8.77 mL, 0.11 mol) in dichloromethane (4.8 mL) were
added dropwise and simultaneously. The mixture was stirred
overnight at room temperature, filtered and the organic layer
was successively washed with NaOH (0.1 M), HCl (0.1 M), H2O
and dried under MgSO4. The solvent was removed under
vacuum and the solid recrystallised in dichloromethane :
hexane – 1 : 10 (v/v). BAP (3) was recovered by filtration and
dried under vacuum at 40 °C. Yield: 5.19 g (52.4%). 1H-NMR
(DMSO-d6) δ (ppm): 3.59 (s, 4H, –CH2–CH2–), 5.71 (dd, 1H, J =
2.3 Hz, J = 10.5 Hz, HCvCHcisHtrans), 6.13 (dd, 1H, J = 2.3 Hz,
J = 16.7 Hz, HCvCHcisHtrans), 6.81 (dd, 1H, J = 10.5 Hz, J = 16.7 Hz,
HCvCHcisHtrans).
13C-NMR (DMSO-d6) δ (ppm): 41.36–45.59





Under nitrogen, BAP (3) (38.85 g, 0.2 mol), 2-methylpiperazine
(15.02 g, 0.1 mol) (4) and N,N′-bis(2-hydroxyethyl)ethylenedi-
amine) (15.25 g, 0.1 mol) (5) were added to 100 mL of H2O.
The reaction was stirred for 3 days at 30 °C. A solution of BAP
(3) (0.78 g, 0.4 mmol) in 5 mL of H2O was then added and the
reaction stirred for one more day. 200 mL of H2O was added
and the pH was adjusted to 2 with HCl (6 M). The PAA (6) was
recovered by ultrafiltration (5 kDa MWCO) followed by freeze
drying. The polymer was further characterised by size exclu-
sion chromatography (SEC) using a PL-GPC 50 system (Varian)
equipped with a RI detector. The sample (5 mg mL−1) was ana-
lysed at 37 °C using PL-aquagel-OH 30 and 40 columns (8 µm;
10 mm × 300 mm). The molecular weight was determined rela-
tive to PEG standards (116 300–3930 g mol−1) [mobile phase:
TRIS (0.1 M, pH = 8.0), 0.5 M NaCl; flow rate: 1 mL min−1].
Yield: 28.34 g (43.9%). 1H-NMR (D2O) δ (ppm): 1.51 (s, 3H,
CH3), 3.05 (m, 7H, methylpiperazine), 3.47–3.65 (m, 8H,
NCH2CH2N, NCH2CH2CO, NCH2CH2OH), 3.87 (m, 8H, piper-
azine), 3.96 (m, 2H, NCH2CH2OH), 5.82 (d, 1H, J = 10.86 Hz,
CHvCHcisHtrans) 6.16 (d, 1H, J = 16.96 Hz, CHvCHcisHtrans),
6.70 (m, 1H, CHvCHcisHtrans). SEC (buﬀer, RI): Mn = 7000 g
mol−1; Mw = 13 200 g mol
−1; PDI = 1.9.
Synthesis of the poly(amidoamine)–BSA conjugates C1 and C2
PAA (6) (8.92 g) was dissolved in H2O (10 mL) and the pH was
adjusted to 8 (conjugate 1 (C1) (7)) or 9 (conjugate 2 (C2) (8))
with NaOH (6 M). BSA (150 mg) in 5 mL of H2O was added
and the reactions were stirred for 8 days at 30 °C. The pH was
maintained (at 8 or 9) throughout. 50 mL of H2O was then
added and the solutions were ultrafiltrated (10 kDa MWCO).
The conjugates were further purified by ionic exchange chrom-
atography (IEX) (Q-Sepharose) and SEC (Superdex 200) using
an ÄKTA Explorer FPLC system (GE Healthcare) equipped with
a fraction collector. Detection was at 280 nm. [IEX: 0–60 min:
PBS (0.1 M, pH = 7); 60–90 min: 0% to 100% PBS (0.1 M, pH =
7), 1 M NaCl; 90–140 min: PBS (0.1 M, pH = 7), 1 M NaCl; flow
rate: 2 mL min−1 – SEC: PBS (10 mM, pH = 7) at 1 mL min−1].
The fractions containing the conjugates were pooled, dialysed
against H2O (5 kDa MWCO) and freeze dried. BSA and PAA
were used as controls. Yields: C1: 47.8 mg, 36.7%; C2: 42.0 mg,
32.2%.
Size exclusion chromatography
The conjugates (100 µL, 1 mg mL−1) were analysed at 37 °C
using the PL-GPC 50 system described previously. Molecular
weights were determined using a PL-aquagel-OH 40 and a PL-
aquagel-OH MIXED-H (8 µm; 10 mm × 300 mm) columns and
protein standards (thyroglobulin (669 kDa), apoferritin
(443 kDa), alcohol dehydrogenase (150 kDa) and carbonic
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anhydrase (29 kDa)) [mobile phase: TRIS (0.1 M, pH = 8),
0.5 M NaCl; flow rate: 1 mL min−1].
Size and zeta potential
Measurements were carried out at 25 °C using a nanoZS zetasi-
zer (Malvern). Zeta potentials were measured using the
Smoluchowski analysis. All samples were prepared in H2O at
the following concentrations: 1 mg mL−1 for size measure-
ments and 3 mg mL−1 (BSA) or 1 mg mL−1 (PAA and conju-
gates) for zeta potential measurements.
Native PAGE electrophoresis
Samples in loading buﬀer (10 µL) were applied onto 4%–12%
native PAGE gels at the following concentrations: BSA (0.5 mg
mL−1), PAA (10 mg mL−1), conjugates (1 and 10 mg mL−1).
Electrophoresis were run for 2 h at 120 V. The gels were
stained for 30 min using solution I, de-stained for 1 h with
solution II and overnight with solution III. Pictures were
recorded using a GBox transilluminator (Syngene).
NativeMark™ unstained proteins (5 µL, 0.2–1 mg mL−1) were
used as standards [loading buﬀer: TRIS (0.05 M, pH = 6.8), 2%
(v/v) glycerol; running buﬀer: TRIS (0.125 M, pH = 8.3), 0.96 M
glycine; solution I: 8% (w/v) coomassie in methanol : acetic
acid 5 : 1 (v/v); solution II: H2O :methanol : acetic acid
65 : 25 : 10 (v/v); solution III: H2O :methanol : acetic acid
88 : 5 : 7 (v/v)].
Protein quantification
The amount of BSA in each conjugate was determined by
quantification of the tryptophan residue using HPLC (Waters
600 pump and Waters 717plus auto sampler connected to a
RF-535 Shimadzu fluorescence detector). The conjugates
(0.5 mg) were first hydrolysed for 2 h in NaOH (3 mL, 6 M) and
at 100 °C. The samples (50 µL) were then analysed using a C18
Eclipse Plus column (5 µm; 4.6 × 100 mm) with detection at
427 nm (λexc = 280 nm) [mobile phase: acetate buﬀer (0.2 M;
pH = 8), 0.02% (w/v) NaN3; flow rate: 2 mL min
−1].
The amount of protein in the conjugates was determined
relative to a calibration curve obtained from BSA samples
(0.05–0.5 mg) subjected to the same treatment.
TNBS assay
50 µL of TNBS (0.34 mM) were added to 100 µL of NaHCO3
(0.1 M, pH = 8.5) containing BSA or a conjugate (0.5 mg mL−1
BSA eq.). The samples were incubated at 37 °C for 4 h and SDS
(50 µL, 0.35 M) and HCl (25 µL, 1 M) were added to stop the
reaction. The absorbances were measured at 335 nm using an
Infinite M200 Pro microplate reader (TECAN).
Enzymatic assay
To 100 µL of native protein or conjugates (2.5 mg mL−1 BSA
eq.) in PBS (0.1 M, pH = 8) was added 10 µL of p-nitrophenyl
acetate (20–60 mM) in acetonitrile and 890 µL of PBS (0.1 M,
pH = 8). The formation of p-nitrophenol at 37 °C was followed
by recording the absorbance at 400 nm every 10 s for 10 min
using appropriate blank reference (UV-1700 Pharma spectro-
photometer (Shimadzu), PCB 150 peltier system (Varian)). The
assay was also carried out after subjecting the protein or the
conjugates to denaturing conditions such as incubation in the
presence of 4 M urea (30 min at room temperature) or incu-




Poly(amidoamine)s are synthesised by step-growth polymer-
isation via Michael-type addition of primary or bis(secondary)
amines to bisacrylamides (Scheme 1).11 They have been used
to promote the delivery of proteins via polymer complexa-
tion.15,17 However, few attempts have been made to develop
bioactive protein–PAA conjugates. Albumin–PAAs have been
prepared via both convergent and divergent methods but
minimal characterisation of the conjugates was provided and
the residual biological activity was not investigated.18,19
Melittin–PAAs were synthesised using a “grafted from”
approach in order to improve the translocation capacity of the
polymers.20 One conjugate demonstrated improved eﬃciency
but the results were mitigated by the associated increased cyto-
toxicity. To synthesise the protein–PAA conjugates, we selected
a poly(amidoamine) based on the structure of ISA1. Earlier
studies reported low cytotoxicity compare to most polycations
(e.g. PEI) and its capacity to deliver non permeant proteins to
the cytosol.14 The structure of the polymer, synthesised with
vinyl terminal groups (5–7 ppm), was confirmed by 1H-NMR.†
The molecular weight, relative to PEG standards, was 13 000 Da
and in solution the polymer formed nanoparticles with an
Scheme 1 Synthesis of poly[(N,N’-bis(acryloyl) piperazine)-co-(2-methylpiperazine)-co-(N,N’-bis(2-hydroxyethyl) ethylenediamine) and the BSA
conjugates.
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average hydrodynamic diameter (Dh) of 75 nm (Table 1). The
PAA was subsequently conjugated to BSA by Michael addition
using a “grafted to” methodology which involved hydrogen-
transfer between the available amino groups of the protein
and the PAA’s acrylamido bond (Scheme 1). BSA has ∼30
lysines accessible for conjugation.21 To react with the activated
acrylamido bond of the polymer, the ε-amino group of the
lysine residues must be unprotonated.22 These ε-amino groups
have a pKa of ∼10.8.
23 However, in the protein, the specific
micro environment surrounding the lysine residues is respon-
sible for decreasing this value to a pKa range of 9.3–9.5.
21,24
The pH of the reaction was initially maintained at 8, but to
favour the conjugation, the reaction was also carried out at pH
9. Zhang et al. demonstrated that increasing the amount of
polymer favoured the formation of the protein–polymer conju-
gate.25 We therefore carried out the conjugation reactions
using a 10 : 1 molar ratio between the PAA and the ε-amino
groups.
Purification of the poly(amidoamine)–BSA conjugates
The “grafted to” conjugation leads to a combination of conju-
gates, unreacted polymer and free protein. The recovered mix-
tures were ultrafiltrated against deionised water and freeze
dried. The conjugates were purified by ion exchange chromato-
graphy (IEX) (Fig. 1a) to remove any free BSA (∼100 min). The
collected fractions (∼20–50 min) were dialysed against water,
freeze dried and further purified by size exclusion chromato-
graphy (SEC) to remove the remaining unreacted PAA (Fig. 1b).
The conjugates eluted at ∼10–15 min while the polymer eluted
at ∼20–30 min.
Physicochemical characterisation of the poly(amidoamine)–
BSA conjugates
The analysis of the samples by native PAGE electrophoresis
clearly demonstrated the presence of some conjugates with
higher molecular weight in comparison to BSA, while no free
protein could be detected (Fig. 2a). The broadness of the
bands reflected the polydispersity of the samples, due to the
presence of diﬀerent conjugates and has been previously
observed.25–27 BSA has been found to adsorb onto nano-
particles coated with amphiphilic polymers28 and we have
demonstrated the formation of complexes with poly(amido-
amine)s which could induce the retardation of the protein.15,29
Control experiments were therefore carried out by mixing free
PAA and free BSA. No bands at higher molecular weight were
observed (Fig. 2b) confirming the formation and detection of
the bioconjugates. The conjugates were further characterised
by SEC and dynamic light scattering (DLS). An increase in the
hydrodynamic diameter and molecular weight was noticed for
both conjugates in comparison to BSA (Table 1). C2 displayed
larger values compare to C1, potentially indicating the
Table 1 Physicochemical characterisation of the conjugates
Mn (Da) Mw (Da) Đ Dh
a (nm) Đa ζ (mV) BSAb (mg mg−1) NH2
c (%)
C1 140 700 208 900 1.5 37.5 ± 1.7 0.47 ± 0.02 +15.4 ± 0.4 0.76 ± 0.03 15.9 ± 0.8
C2 218 600 530 400 2.4 75.1 ± 1.8 0.54 ± 0.02 +20.2 ± 1.0 0.43 ± 0.09 24.8 ± 1.0
BSA 102 500 120 200 1.2 5.9 ± 0.3 0.31 ± 0.01 −11.7 ± 1.9 — —
PAA 7000 13 200 1.9 73.5 ± 10.7 0.47 ± 0.07 +44.8 ± 2.3 — —
Mn: number average molecular weight. Mw: weight average molecular weight. Đ: polydispersity. Mn, Mw and Đ were determined by SEC relative to
protein standards for the conjugates and BSA and relative to PEG standards for PAA. Dh: hydrodynamic diameter. ζ: zeta potential.
aDetermined
by DLS. bmg of BSA per mg of conjugate. c% of primary amine modified following conjugation to PAA. Mean ± SD, n = 3.
Fig. 1 Puriﬁcation of the conjugates. Panel (a): Free BSA was removed
by IEX (0–60 min (PBS); 60–90 min (0 to 100% PBS/NaCl); 90–140 min
(PBS/NaCl); 2 mL min−1). Panel (b): Collected fractions were further
puriﬁed by SEC (PBS; 1 mL min−1) to remove free PAA. Collected frac-
tions were dialysed against H2O and freeze dried before further analysis.
BSA and PAA were used as control for IEX and SEC, respectively.
Fig. 2 Native PAGE analysis of the puriﬁed conjugates at low and high
concentrations (a) and a mixture of BSA and PAA corresponding to the
composition of C1 and C2 at low and high concentrations (b). BSA
(0.5 mg mL−1) and PAA (10 mg mL−1) were used as control. Free PAA did
not elute.
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presence of a higher number of PAA chains attached to the
protein. The polydispersity of the samples observed in the
acrylamide gels (Fig. 2) was also apparent from these results
and is due to the conjugation method which did not allow
control of the conjugation. BSA has two tryptophan residues.
The amount of protein per milligrams of conjugate was deter-
mined by quantifying the tryptophan content of the samples.
Both conjugates were subjected to alkaline hydrolysis and
analysed by HPLC. C1 possessed the highest amount of BSA
per mg of conjugate (Table 1). These results were correlated to
the percentage of modified amine following conjugation with
the polymer. The remaining percentage of free primary
amines, relative to unconjugated BSA, was determined using a
TNBS assay (Table 1).30 C1 had ∼84% of unmodified amines
while C2 had only ∼75%. These results are in agreement with
the conjugates BSA content and the conjugates relative size
obtained by SEC and DLS (Table 1). As expected, the zeta
potential measurements demonstrated that conjugation of the
polymer chains to BSA, modified the protein surface charge.31
The poly(amidoamine) used in the conjugation being cationic
(+44.8 mV), both conjugates displayed a positive potential
(+15.4 mV and +20.2 mV) in comparison to BSA (−11.7 mV)
(Table 1).
Enzymatic activity
BSA has been frequently used as a model protein to investigate
diﬀerent bioconjugation strategies.11,18,32–37 The conjugation
of polymers to proteins can aﬀect the protein stability and/or
bioactivity. Factors such as the nature of the modified amino
acids, the structure and physicochemical properties of the
polymer or the method used for the conjugation or the ligation
strategy can influence the protein activity either positively (i.e.
increased activity) or negatively (i.e. decreased activity).16 BSA
catalyses the hydrolysis of p-nitrophenyl acetate to nitrophenol,
the reaction can be monitored by following product formation
at 400 nm.38 Previous studies have reported the synthesis of
polymer–BSA conjugates which, at room temperature, had a
residual activity between 63 to 94% of the native protein.39–42
The esterase-like enzymatic activities of the conjugates were
determined at 37 °C (Fig. 3). Under non-denaturing condition,
C1 displayed 104% (±3%) activity of the non-modified BSA,
while C2 retained only 35% (±0.3%). The decreased activity of
C2 could be linked to the higher degree of amine modification
obtained at pH 9 (Table 1). This correlation has been pre-
viously observed for other conjugates.42,43 Seo et al. developed
PMPC–BSA conjugates which retained full activity after incu-
bation at 64 °C for 5 min.44 Under similar stress conditions
(10 min at 50 °C) C1 and C2 retained 71% (±1%) and 20%
(±0.5%) activity, respectively. In the presence of 4 M urea
both conjugates displayed an activity around 20% (±0.4%).
Upon conjugation, modification of the aﬃnity between the
substrate and the enzyme has been reported for diﬀerent
conjugates.45–50 The enzyme kinetics of BSA, C1 and C2 was
investigated and the kinetic parameters (Vmax, KM and kcat)
were determined from Lineweaver–Burk plots (Fig. 4). Under
normal conditions, BSA and C1 showed similar linear curves
Fig. 3 Relative residual enzymatic activities under non-denaturing
(37 °C) and denaturing conditions (50 °C and urea). All residual activities
are relative to the enzymatic activity of the non-modiﬁed BSA, which
was 12.5 μmol min−1 g−1 protein. Mean ± SD, n = 3.
Fig. 4 Lineweaver–Burk plots for BSA (green), C1 (red) and C2 (blue). (a) 37 °C (b) 50 °C and (c) urea. The Michaelis–Menten kinetic parameters
were obtained by nonlinear regression using the Lineweaver–Burk equation. Mean ± SD, n = 3.
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(Fig. 4a). A small increase of KM was observed for C1 indicating
a potential decrease of the aﬃnity for the substrate (Table 2).
However, this did not significantly aﬀect kcat/KM as C1 dis-
played a catalytic eﬃciency (kcat/KM = 84.5 (M s)
−1) similar to
BSA (kcat/KM = 87.5 (M s)
−1). Following incubation at 50 °C for
10 min, the Lineweaver–Burk plot for BSA deviated from linear-
ity, whereas C1 still displayed a linear plot (Fig. 4b). Similar
deviation has been observed for C2 at 37 °C. Such deviation
has been observed for other enzymes and has been attributed
to substrate activation, cooperative interactions, presence of
isoenzymes or multiple enzymes catalysing the same reac-
tion.51,52 When subjected to an increase in temperature, BSA is
denatured and upon quenching of the temperature, only a frac-
tion of the protein will refold correctly.53 This could lead to
the presence of diﬀerent protein structures in solution, each
with diﬀerent aﬃnity towards the substrate, and could poten-
tially explain the deviation from linearity. In this case, the
kinetic parameters extracted from the low substrate concen-
trations of the Lineweaver–Burk plots should be considered
cautiously as they will only characterise the enzyme with the
highest aﬃnity for the substrate.53 This is reflected by the
10-fold decrease of the KM for BSA. In the case of C1, we noted
a ∼4-fold decrease of the conjugate aﬃnity corresponding to a
lower catalytic eﬃciency (kcat/KM = 50.8 (M s)
−1) but we did not
detect a deviation from linearity, which may indicate some pro-
tecting eﬀect. In the presence of 4 M urea (Fig. 4c), all the
Lineweaver–Burk plots deviated from linearity potentially indi-
cating the presence of diﬀerent protein and conjugate confor-
mation and no protection against urea denaturation.
Conclusions
Poly(amidoamine)–BSA conjugates were successfully syn-
thesised using a “grafted to” method. The conjugation to
lysine residues was carried out using mild conditions at room
temperature and in an aqueous environment. Following purifi-
cation by chromatography, the conjugates were fully character-
ised. Under non denaturing conditions, the residual enzymatic
activity of the bioconjugates correlated with the percentage of
conjugated lysine residues. Exposure to increased temperature
led to a decrease of the catalytic eﬃciency but, as opposed to
the native protein, without evidence of formation of intermedi-
ates. To date poly(amidoamine)s have been essentially used for
biomedical applications to promote cellular delivery of bio-
macromolecules. The same methodology could be used for
therapeutic proteins with an intracellular pharmacological
target but could also have potential applications in the field of
biocatalysis and biosensors.
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